Compare Matson Inc (MATX) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Matson Inc vs TransMedics Group Inc — how do they compare? Matson Inc trades at $225.67 (market cap $6.81B), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: Matson Inc is far larger — about 2.5× TransMedics Group Inc's market cap, and Matson Inc pays a 0.67% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Matson Inc for 23 Days and TransMedics Group Inc for 24 Days on average.
| MATX | TMDX | |
|---|---|---|
Market Cap | $6.81B | $2.74B |
Volume | 255,080 | 949,331 |
Sector | Industrials | Health |
52-Week High | $238.60 | $150.42 |
52-Week Low | $88.05 | $61.99 |
Typical Hold Time | 23 Days | 24 Days |
Enterprise Value | $7.41B | $3.13B |
Dividend Yield | 0.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Matson (MATX) trades at $227.79, up 2.18% with strong bullish technical signals and consistent earnings beats. The stock shows robust fundamentals with 13.41% net income margin and 17.21% ROE, supported by positive analyst sentiment (66.7% buy ratings). Recent Q2 2026 earnings of $4.27 per share exceeded expectations by 12.7%, with the company raising full-year guidance amid resilient consumer demand and stable Trans-Pacific trade conditions.
Outlook remains positive with projected revenue growth to $3.5B in 2026 and improved cash flow. Key risks include freight market volatility and competitive pressures. Wall Street sees 27.3% upside potential based on average price targets, while institutional buying activity from Bank of America and Deutsche Bank signals confidence in the company's execution.
TMDX trades at $79.00, down 2.55% amid bearish technical signals. The stock shows strong profitability with 22.69% net margin and 36.28% ROE, though recent earnings misses and margin compression from 2025 to 2026 raise concerns. Analyst consensus remains bullish with a $99.75 price target, but multiple legal investigations into fiduciary duties create uncertainty. Revenue growth continues with 2026 guidance at $668M.
The stock presents a growth opportunity with analyst upside potential, but faces near-term headwinds from earnings volatility and legal scrutiny. Execution on 2026 guidance and resolution of governance concerns will be critical for sustained momentum. Current valuation at 20.47 P/E appears reasonable given growth prospects if operational targets are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Matson Inc
Matson, Inc. is an American shipping and logistics company primarily operating in the Pacific. The company provides ocean transportation services, including container, automobile, and general cargo, particularly between the U.S. West Coast, Hawaii, Alaska, and Guam. Matson also offers logistics services, including warehousing, less-than-container load (LCL) consolidation, and supply chain management, making it a critical service provider for businesses operating across the Pacific region.
Read more on MATX →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
